Mocravimod Study Overview: This study is testing a medicine called mocravimod for people with acute myeloid leukemia (AML) who are getting a type of cell transplant known as allogeneic hematopoietic cell transplantation (HCT). The study checks if mocravimod helps and is safe as an extra and ongoing treatment. AML is a cancer that affects blood and bone marrow. Allogeneic HCT is when patients receive healthy blood-forming cells from a donor.

Eligibility: Participants must be adults aged 18-75 with a specific type of AML. They should have a matched donor for the transplant and plan to use certain medicines to prevent complications.

• This study is double-blinded, meaning neither you nor the doctor will know if you get mocravimod or a placebo (a dummy treatment).
• Participants need to meet specific health criteria to join and cannot have certain conditions like liver or kidney problems.
• The study is happening at multiple centers, and participants must be able to travel for visits.